DOP2021000039A - Administración prolongada de lasmiditan por la noche para la prevención de la migraña - Google Patents

Administración prolongada de lasmiditan por la noche para la prevención de la migraña

Info

Publication number
DOP2021000039A
DOP2021000039A DO2021000039A DO2021000039A DOP2021000039A DO P2021000039 A DOP2021000039 A DO P2021000039A DO 2021000039 A DO2021000039 A DO 2021000039A DO 2021000039 A DO2021000039 A DO 2021000039A DO P2021000039 A DOP2021000039 A DO P2021000039A
Authority
DO
Dominican Republic
Prior art keywords
migraine
prevention
night
meditan
prolonged administration
Prior art date
Application number
DO2021000039A
Other languages
English (en)
Inventor
Russell Conley Robert
Davar Gudarz
Willis Johnson Kirk
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68051892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2021000039(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2021000039A publication Critical patent/DOP2021000039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere al uso prolongado de lasmiditan por la noche para la prevención de la migraña, particularmente la migraña resistente al tratamiento que se define en el presente documento como migraña refractaria a dos o más esquemas de prevención o tratamiento previos de monoterapia y/o terapia doble.
DO2021000039A 2018-09-04 2021-03-02 Administración prolongada de lasmiditan por la noche para la prevención de la migraña DOP2021000039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726585P 2018-09-04 2018-09-04
PCT/US2019/049340 WO2020051137A1 (en) 2018-09-04 2019-09-03 Chronic nightly dosing of lasmiditan for migraine prevention

Publications (1)

Publication Number Publication Date
DOP2021000039A true DOP2021000039A (es) 2021-03-31

Family

ID=68051892

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000039A DOP2021000039A (es) 2018-09-04 2021-03-02 Administración prolongada de lasmiditan por la noche para la prevención de la migraña

Country Status (36)

Country Link
US (1) US12138254B2 (es)
EP (2) EP4279132A3 (es)
JP (2) JP7321256B2 (es)
KR (1) KR102649644B1 (es)
CN (1) CN112638383A (es)
AU (3) AU2019336667B2 (es)
BR (1) BR112021002945A2 (es)
CL (1) CL2021000529A1 (es)
CO (1) CO2021002766A2 (es)
CR (1) CR20210126A (es)
DK (1) DK3846810T3 (es)
DO (1) DOP2021000039A (es)
EA (1) EA202190440A1 (es)
EC (1) ECSP21015491A (es)
ES (1) ES2967665T3 (es)
FI (1) FI3846810T3 (es)
HR (1) HRP20231587T1 (es)
HU (1) HUE064519T2 (es)
IL (1) IL281208B2 (es)
JO (1) JOP20210033B1 (es)
LT (1) LT3846810T (es)
MA (1) MA53551B1 (es)
MD (1) MD3846810T2 (es)
MX (1) MX2021002474A (es)
MY (1) MY199662A (es)
PE (1) PE20211599A1 (es)
PH (1) PH12021550448A1 (es)
PL (1) PL3846810T3 (es)
PT (1) PT3846810T (es)
RS (1) RS64857B1 (es)
SG (1) SG11202101530PA (es)
SI (1) SI3846810T1 (es)
TW (1) TWI826514B (es)
UA (1) UA129587C2 (es)
WO (1) WO2020051137A1 (es)
ZA (1) ZA202100666B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2413933T5 (pl) 2009-04-02 2021-10-18 Colucid Pharmaceuticals, Inc. 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną
JP6491669B2 (ja) 2014-02-05 2019-03-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ活性化合物の錠剤製剤
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN116390712A (zh) * 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5521196A (en) 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5698571A (en) 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
NZ305166A (en) 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
US5942536A (en) 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
US5708187A (en) 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
BR9711273A (pt) 1996-08-28 1999-08-17 Lilly Co Eli 1,2,3,4- Tetraidro-2-dibenzofuranaminas substituidas e 2- aminociclohepta b benzofuranos
AU4652697A (en) 1996-10-08 1998-05-05 Eli Lilly And Company New serotonin 5-ht1f agonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU4961499A (en) 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
JP2002519348A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
US6608079B1 (en) 1998-12-11 2003-08-19 Eli Lilly And Company Indole derivatives and their use as 5-HT1F agonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
DE60036924T2 (de) 1999-02-10 2008-08-14 Eli Lilly And Co., Indianapolis 5-ht1f agonisten
AU3354000A (en) 1999-02-26 2000-09-14 Eli Lilly And Company 5-ht1f agonists
WO2002006196A1 (en) 2000-07-13 2002-01-24 Merck Patent Gmbh Chiral compounds i
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
WO2003000245A1 (en) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
AU2003295782A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
MXPA05011223A (es) 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
AU2005311251A1 (en) 2004-12-01 2006-06-08 Devgen Nv 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family
KR20060067738A (ko) 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
KR100976063B1 (ko) 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
PL2413933T5 (pl) * 2009-04-02 2021-10-18 Colucid Pharmaceuticals, Inc. 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną
US8697876B2 (en) * 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
KR20190075130A (ko) 2016-12-06 2019-06-28 코루시드 파마슈티컬즈 인코포레이티드 피리디노일피페리딘 5-ht1f 작용제에 관한 조성물 및 방법
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
PE20211599A1 (es) 2021-08-18
EP4279132A3 (en) 2024-03-06
AU2019336667A1 (en) 2021-03-11
IL281208B2 (en) 2025-02-01
SG11202101530PA (en) 2021-03-30
FI3846810T3 (fi) 2023-12-15
ECSP21015491A (es) 2021-04-29
EP4279132A2 (en) 2023-11-22
MX2021002474A (es) 2021-08-24
HUE064519T2 (hu) 2024-03-28
TW202033197A (zh) 2020-09-16
MA53551A (fr) 2022-01-12
PH12021550448A1 (en) 2021-09-27
UA129587C2 (uk) 2025-06-11
ZA202100666B (en) 2024-09-25
IL281208B1 (en) 2024-10-01
CR20210126A (es) 2021-04-22
WO2020051137A1 (en) 2020-03-12
RS64857B1 (sr) 2023-12-29
TWI826514B (zh) 2023-12-21
HRP20231587T1 (hr) 2024-03-15
IL281208A (en) 2021-04-29
PT3846810T (pt) 2023-12-14
NZ774400A (en) 2024-03-22
EP3846810B1 (en) 2023-10-18
EA202190440A1 (ru) 2021-06-24
MD3846810T2 (ro) 2024-04-30
US20210338655A1 (en) 2021-11-04
DK3846810T3 (da) 2023-12-04
JOP20210033A1 (ar) 2021-02-25
CA3111205A1 (en) 2020-03-12
KR102649644B1 (ko) 2024-03-21
EP3846810A1 (en) 2021-07-14
CN112638383A (zh) 2021-04-09
JP2021535913A (ja) 2021-12-23
JP7543497B2 (ja) 2024-09-02
AU2022291568A1 (en) 2023-02-02
AU2025201479A1 (en) 2025-03-20
BR112021002945A2 (pt) 2021-05-11
SI3846810T1 (sl) 2023-12-29
JP7321256B2 (ja) 2023-08-04
CO2021002766A2 (es) 2021-03-19
JOP20210033B1 (ar) 2024-04-18
CL2021000529A1 (es) 2021-08-13
KR20210039419A (ko) 2021-04-09
MY199662A (en) 2023-11-15
US12138254B2 (en) 2024-11-12
PL3846810T3 (pl) 2024-03-18
AU2019336667B2 (en) 2022-09-29
MA53551B1 (fr) 2023-11-30
LT3846810T (lt) 2024-01-10
JP2023156344A (ja) 2023-10-24
ES2967665T3 (es) 2024-05-03

Similar Documents

Publication Publication Date Title
DOP2021000039A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
MX378969B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
CL2017002904A1 (es) Métodos y kits para tratar la depresión
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
MX2020002554A (es) Terapia combinada de lasmiditan y un antagonista de cgrp para el uso en el tratamiento de la migraña.
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
CR20180495A (es) Deribados de indol sustituidos como inhibidores de replicación viral del dengue
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2021003602A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
EP3843715C0 (en) THERAPY OF HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTIONS